Imbalance between endothelial damage and repair: A gateway to cardiovascular disease in systemic lupus erythematosus

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Mak, Anselm ^a,b   Kow, Nien Yee ^b  

^a University Medicine Cluster   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; AUTOANTIBODY; C REACTIVE PROTEIN; CD137 ANTIGEN; CD137 LIGAND; CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; INTERFERON; INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; RETINOIC ACID RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN ANTIBODY COMPLEX; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AWARENESS; BLOOD VESSEL DIAMETER; BLOOD VESSEL INJURY; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CELL DAMAGE; CHRONIC INFLAMMATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; FLOW MEDIATED VASODILATION; HUMAN; INFLAMMATORY CELL; NEUTROPHIL; NEUTROPHIL EXTRACELLULAR TRAP; NONHUMAN; OXIDATIVE STRESS; PHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SHEAR STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM; VASODILATATION; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOPHYSIOLOGY; VASCULAR REMODELING;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, CARDIOVASCULAR; VASCULAR REMODELING;

EID: 84899568817     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/178721     Document Type: Review

References (127)

1. Wahren-Herlenius M., Dörner T., Immunopathogenic mechanisms of systemic autoimmune disease. The Lancet 2013 382 9894 819 831 10.1016/S0140-6736(13)60954-X
2. Mak A., Cheung M. W., Chiew H. J., Liu Y., Ho R. C., Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Seminars in Arthritis and Rheumatism 2012 41 6 830 839 2-s2.0-84855753199 10.1016/j.semarthrit.2011.11.002
3. Bernatsky S., Boivin J. F., Joseph L., Manzi S., Ginzler E., Gladman D. D., Urowitz M., Fortin P. R., Petri M., Barr S., Gordon C., Bae S. C., Isenberg D., Zoma A., Aranow C., Dooley M. A., Nived O., Sturfelt G., Steinsson K., Alarcón G., Senécal J. L., Zummer M., Hanly J., Ensworth S., Pope J., Edworthy S., Rahman A., Sibley J., El-Gabalawy H., McCarthy T., St. Pierre Y., Clarke A., Ramsey-Goldman R., Mortality in systemic lupus erythematosus. Arthritis and Rheumatism 2006 54 8 2550 2557 2-s2.0-33746936116 10.1002/art.21955 (Pubitemid 44205016)
4. Hak A. E., Karlson E. W., Feskanich D., Stampfer M. J., Costenbader K. H., Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Care and Research 2009 61 10 1396 1402 2-s2.0-70349774430 10.1002/art.24537
5. Manzi S., Meilahn E. N., Rairie J. E., Conte C. G., Medsger T. A. Jr., Jansen-McWilliams L., D'Agostino R. B., Kuller L. H., Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. The American Journal of Epidemiology 1997 145 5 408 415 2-s2.0-0031052874 (Pubitemid 27084212)
6. Bäck J., Lood C., Bengtsson A. A., Ekdahl K. N., Nilsson B., Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus. Arthritis Research and Therapy 2013 15 6, article R206
7. López-Mejías R., García-Bermúdez M., González-Juanatey C., Castañeda S., Miranda-Filloy J. A., Gómez-Vaquero C., Fernández-Gutiérrez B., Balsa A., Pascual-Salcedo D., Blanco R., González-Álvaro I., Llorca J., Martín J., González-Gay M. A., NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2012 224 2 426 429 10.1016/j. atherosclerosis.2012.06.008
8. López-Mejías R., Genre F., García-Bermúdez M., Castañeda S., González-Juanatey C., Llorca J., Corrales A., Miranda-Filloy J. A., Rueda-Gotor J., Gómez-Vaquero C., Rodríguez-Rodríguez L., Fernández-Gutiérrez B., Balsa A., Pascual-Salcedo D., López-Longo F. J., Carreira P., Blanco R., González-Álvaro I., Martín J., González-Gay M. A., The 11q23.3 genomic region-rs964184-is associated with cardiovascular disease in patients with rheumatoid arthritis. Tissue Antigens 2013 82 5 344 347 10.1111/tan.12217
9. López-Mejías R., González-Juanatey C., García-Bermúdez M., Castañeda S., Miranda-Filloy J. A., Blanco R., Llorca J., Martín J., González-Gay M. A., The lp13.3 genomic region-rs599839-is associated with endothelial dysfunction in patients with rheumatoid arthritis. Arthritis Research and Therapy 2012 14 2, article R42
10. López-Mejías R., Genre F., García-Bermúdez M., Corrales A., González-Juanatey C., Llorca J., Miranda-Filloy J. A., Rueda-Gotor J., Blanco R., Castañeda S., Martín J., González-Gay M. A., The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritis. Arthritis Research and Therapy 2013 15 5, article R152
11. Leonard D., Svenungsson E., Sandling J. K., Berggren O., Jönsen A., Bengtsson C., Wang C., Jensen-Urstad K., Granstam S. O., Bengtsson A. A., Gustafsson J. T., Gunnarsson I., Rantapää-Dahlqvist S., Nordmark G., Eloranta M. L., Syvänen A. C., Rönnblom L., Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circulation: Cardiovascular Genetics 2013 6 3 255 263 10.1161/CIRCGENETICS.113.000044
12. Bahrehmand F., Vaisi-Raygani A., Kiani A., Rahimi Z., Tavilani H., Navabi S. J., Shakiba E., Hassanzadeh N., Pourmotabbed T., Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus 2012 21 6 616 624 2-s2.0-84859912781 10.1177/0961203312436857
13. Bicakcigil M., Tasan D. A., Tasdelen N., Mutlu N., Yavuz S., Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients. Lupus 2011 20 10 1063 1071 2-s2.0-80052888574 10.1177/0961203311404911
14. Troelsen L. N., Garred P., Christiansen B., Torp-Pedersen C., Jacobsen S., Genetically determined serum levels of mannose-binding lectin correlate negatively with common carotid intima-media thickness in systemic lupus erythematosus. Journal of Rheumatology 2010 37 9 1815 1821 2-s2.0-77956483576 10.3899/jrheum.100158
15. Marasini B., Massarotti M., de Monti M., Erario M., Ghilardi G., Biondi M. L., Genetic contribution to carotid vascular disease in patients with systemic lupus erythematosus. Journal of Clinical Immunology 2008 28 2 131 133 2-s2.0-40149084552 10.1007/s10875-007-9146-3
16. Szalai A. J., Alarcón G. S., Calvo-Alén J., Toloza S. M. A., McCrory M. A., Edberg J. C., McGwin G. Jr., Bastian H. M., Fessler B. J., Vilá L. M., Kimberly R. P., Reveille J. D., Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology 2005 44 7 864 868 2-s2.0-22844435417 10.1093/rheumatology/keh613 (Pubitemid 41511179)
17. Mak A., Isenberg D. A., Lau C. S., Global trends, potential mechanisms and early detection of organ damage in SLE. Nature Reviews Rheumatology 2013 9 5 301 310
18. Kao A. H., Lertratanakul A., Elliott J. R., Sattar A., Santelices L., Shaw P., Birru M., Avram Z., Thompson T., Sutton-Tyrrell K., Ramsey-Goldman R., Manzi S., Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. The American Journal of Cardiology 2013 112 7 1025 1032 10.1016/j.amjcard.2013.05.040
19. Kiani A. N., Post W. S., Magder L. S., Petri M., Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology 2011 50 11 2071 2079 2-s2.0-84855183264
20. Tyrrell P. N., Beyene J., Feldman B. M., McCrindle B. W., Silverman E. D., Bradley T. J., Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 5 1014 1026 2-s2.0-77951489475 10.1161/ATVBAHA.109.198424
21. Petri M. A., Kiani A. N., Post W., Christopher-Stine L., Magder L. S., Lupus atherosclerosis prevention study (LAPS). Annals of the Rheumatic Diseases 2011 70 5 760 765 2-s2.0-79953324124 10.1136/ard.2010.136762
22. Plazak W., Pasowicz M., Kostkiewicz M., Podolec J., Tomkiewicz-Pajak L., Musial J., Podolec P., Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflammation Research 2011 60 10 973 980 2-s2.0-80955158816 10.1007/s00011-011-0358-x
23. Von Feldt J. M., Eisner E. R., Sawaires A., Coronary electron beam computed tomography in 13 patients with systemic lupus erythematosus and two or more cardiovascular risk factors. Journal of Clinical Rheumatology 2002 8 6 316 321 2-s2.0-0036899524 (Pubitemid 35453598)
24. Yiu K. H., Schouffoer A. A., Marsan N. A., Ninaber M. K., Stolk J., Vlieland T. V., Scherptong R. W., Delgado V., Holman E. R., Tse H. F., Huizinga T. W. J., Bax J. J., Schuerwegh A. J. M., Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: relationship to functional capacity and ventricular arrhythmias. Arthritis and Rheumatism 2011 63 12 3969 3978 2-s2.0-82455210463 10.1002/art.30614
25. Yiu K. H., Tse H. F., Mok M. Y., Lau C. S., Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. Nature Reviews Rheumatology 2011 7 10 609 618 2-s2.0-80053913306 10.1038/nrrheum.2011.126
26. Lau C. S., Cheung T., Should clinicians start measuring flow mediated dilation response in patients with systemic lupus erythematosus? Journal of Rheumatology 2011 38 7 1231 1233 2-s2.0-79959976107 10.3899/jrheum.110635
27. Aizer J., Karlson E. W., Chibnik L. B., Costenbader K. H., Post D., Liang M. H., Gall V., Gerhard-Herman M. D., A controlled comparison of brachial artery flow mediated dilation (FMD) and digital pulse amplitude tonometry (PAT) in the assessment of endothelial function in systemic lupus erythematosus. Lupus 2009 18 3 235 242 2-s2.0-60449093169 10.1177/0961203308096663
28. Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., Shoenfeld Y., Szegedi G., Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. Journal of Autoimmunity 2006 27 4 211 217 2-s2.0-33846810195 10.1016/j.jaut.2006.09.008 (Pubitemid 46206103)
29. Johnson S. R., Harvey P. J., Floras J. S., Iwanochko M., Ibanez D., Gladman D. D., Urowitz M., Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus 2004 13 8 590 593 2-s2.0-4344573862 10.1191/0961203304lu1072oa (Pubitemid 39145488)
30. El-Magadmi M., Bodill H., Ahmad Y., Durrington P. N., Mackness M., Walker M., Bernstein R. M., Bruce I. N., Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004 110 4 399 404 2-s2.0-3342912111 10.1161/01.CIR.0000136807.78534.50 (Pubitemid 38993848)
31. Inoue T., Matsuoka H., Higashi Y., Ueda S., Sata M., Shimada K., Ishibashi Y., Node K., Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertension Research 2008 31 12 2105 2113 2-s2.0-61949163918 10.1291/hypres.31.2105
32. Drexler H., Hornig B., Endothelial dysfunction in human disease. Journal of Molecular and Cellular Cardiology 1999 31 1 51 60 2-s2.0-0032990560 10.1006/jmcc.1998.0843 (Pubitemid 29078218)
33. Rubanyi G. M., The role of endothelium in cardiovascular homeostasis and diseases. Journal of Cardiovascular Pharmacology 1993 22 supplement 4 S1 S14 2-s2.0-0027445164 (Pubitemid 23329995)
34. Bauer V., Sotníková R., Nitric oxide-the endothelium-derived relaxing factor and its role in endothelial functions. General Physiology and Biophysics 2010 29 4 319 340 10.4149/gpb-2010-04-319
35. Lei H., Luo S., Qin H., Xia Y., Molecular mechanisms of endothelial NO synthase uncoupling. Current Pharmaceutical Design 2013 10.2174/ 13816128113196660746
36. Anderson T. J., Gerhard M. D., Meredith I. T., Charbonneau F., Delagrange D., Creager M. A., Selwyn A. P., Ganz P., Systemic nature of endothelial dysfunction in atherosclerosis. The American Journal of Cardiology 1995 75 6 71B 74B 2-s2.0-0028943790
37. Halcox J. P. J., Schenke W. H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M. A., Nour K. R. A., Quyyumi A. A., Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002 106 6 653 658 2-s2.0-0037031266 10.1161/01.CIR.0000025404.78001.D8 (Pubitemid 34851922)
38. de Caterina R., Libby P., Peng H. B., Thannickal V. J., Rajavashisth T. B., Gimbrone M. Jr., Shin W. S., Liao J. K., Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. Journal of Clinical Investigation 1995 96 1 60 68 2-s2.0-0029159779
39. Blum A., Miller H., The effects of L-arginine on atherosclerosis and heart disease. International Journal of Cardiovascular Interventions 1999 2 2 97 100 2-s2.0-0033019619 (Pubitemid 29317840)
40. Ewart M., Kohlhaas C. F., Salt I. P., Inhibition of tumor necrosis factor α -stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 12 2255 2257 2-s2.0-57549088860 10.1161/ATVBAHA.108.175919
41. Moore C., Sanz-Rosa D., Emerson M., Distinct role and location of the endothelial isoform of nitric oxide synthase in regulating platelet aggregation in males and females in vivo. European Journal of Pharmacology 2011 651 1-3 152 158 2-s2.0-78650679530 10.1016/j.ejphar.2010.11.011
42. Lima D. S. N., Sato E. I., Lima V. C., Miranda F. Jr., Hatta F. H., Brachial endothelial function is impaired in patients with systemic lupus erythematosus. Journal of Rheumatology 2002 29 2 292 297 2-s2.0-0036158406 (Pubitemid 34118776)
43. Mak A., Liu Y., Ho R. C., Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: a metaanalysis and metaregression. Journal of Rheumatology 2011 38 7 1296 1303 2-s2.0-79959952893 10.3899/jrheum.101182
44. Liu X., Zhang G. X., Zhang X. Y., Xia W. H., Yang Z., Su C., Qiu Y. X., Xu S. Y., Zhan H., Tao J., Lacidipine improves endothelial repair capacity of endothelial progenitor cells from patients with essential hypertension. International Journal of Cardiology 2013 168 4 3317 3326 10.1016/j.ijcard.2013. 04.041
45. Moon J. H., Chae M. K., Kim K. J., Kim H. M., Cha B. S., Lee H. C., Kim Y. J., Lee B. W., Decreased endothelial progenitor cells and increased serum glycated albumin are independently correlated with plaque-forming carotid artery atherosclerosis in type 2 diabetes patients without documented ischemic disease. Circulation Journal 2012 76 9 2273 2279 10.1253/circj.CJ-11-1499
46. Suzuki R., Fukuda N., Katakawa M., Tsunemi A., Tahira Y., Matsumoto T., Ueno T., Soma M., Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension. The American Journal of Hypertension 2013
47. Urbich C., Dimmeler S., Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney International 2005 67 5 1672 1676 2-s2.0-17744388581 10.1111/j.1523-1755.2005.00261.x (Pubitemid 40577698)
48. Tsai N. W., Hung S. H., Huang C. R., Chang H. W., Chang W. N., Lee L. H., Wang H. C., Lin Y. J., Lin W. C., Cheng B. C., Chiang Y. F., Su Y. J., Tsai T. R., Lu C. H., The association between circulating endothelial progenitor cells and outcome in different subtypes of acute ischemic stroke. Clinica Chimica Acta 2014 427 6 10 10.1016/j.cca.2013.09.029
49. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., Böhm M., Nickenig G., Circulating endothelial progenitor cells and cardiovascular outcomes. The New England Journal of Medicine 2005 353 10 999 1007 2-s2.0-24344442873 10.1056/NEJMoa043814 (Pubitemid 41262334)
50. Mok M. Y., Yiu K. H., Wong C. Y., Qiuwaxi J., Lai W. H., Wong W. S., Tse H. F., Lau C. S., Low circulating level of CD133+KDR+cells in patients with systemic sclerosis. Clinical and Experimental Rheumatology 2010 28 5, supplement 62 S19 S25 2-s2.0-78650557653
51. Kuwana M., Okazaki Y., Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Annals of the Rheumatic Diseases 2012 71 4 617 620 2-s2.0-84857924684 10.1136/annrheumdis-2011-200713
52. Castejon R., Jimenez-Ortiz C., Valero-Gonzalez S., Rosado S., Mellor S., Yebra-Bango M., Decreased circulating endothelial progenitor cells as an early risk factor of subclinical atherosclerosis in systemic lupus erythematosus. Rheumatology 2013 10.1093/rheumatology/ket367
53. Rodríguez-Carrio J., Prado C., de Paz B., López P., Gómez J., Alperi-López M., Ballina-García F. J., Suárez A., Circulating endothelial cells and their progenitors in systemic lupus erythematosus and early rheumatoid arthritis patients. Rheumatology 2012 51 10 1775 1784 10.1093/rheumatology/kes152
54. Moonen J. R. A. J., de Leeuw K., van Seijen X. J. G. Y., Kallenberg C. G. M., van Luyn M. J. A., Bijl M., Harmsen M. C., Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Research and Therapy 2007 9 4, article R84 2-s2.0-34948892057 10.1186/ar2283 (Pubitemid 47517251)
55. Kaplan M. J., Premature vascular damage in systemic lupus erythematosus. Autoimmunity 2009 42 7 580 586 2-s2.0-71049165046 10.1080/08916930903002479
56. Hooks J. J., Moutsopoulos H. M., Geis S. A., Stahl N. I., Decker J. L., Notkins A. L., Immune interferon in the circulation of patients with autoimmune disease. The New England Journal of Medicine 1979 301 1 5 8 2-s2.0-0018775078 (Pubitemid 9226519)
57. Yee A. M., Yip Y. K., Fischer H. D., Buyon J. P., Serum activity that confers acid lability to α -interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating α -interferon. Arthritis and Rheumatism 1990 33 4 563 568 2-s2.0-0025357153 10.1002/art.1780330414 (Pubitemid 20151243)
58. Rus V., Zernetkina V., Puliaev R., Cudrici C., Mathai S., Via C. S., Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clinical Immunology 2005 117 1 48 56 2-s2.0-27244440325 10.1016/j.clim.2005.05.001 (Pubitemid 41725469)
59. Secchiero P., Rimondi E., di Iasio M. G., Agnoletto C., Melloni E., Volpi I., Zauli G., C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway. Clinical Cancer Research 2013 19 8 1949 1959 10.1158/1078-0432.CCR-12-3027
60. Di Bartolo B. A., Cartland S. P., Harith H. H., Bobryshev Y. V., Schoppet M., Kavurma M. M., TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS ONE 2013 8 9 e74211
61. Niessner A., Weyand C. M., Dendritic cells in atherosclerotic disease. Clinical Immunology 2010 134 1 25 32 2-s2.0-71649103144 10.1016/j.clim.2009.05. 006
62. Higashiyama M., Hokari R., Kurihara C., Ueda T., Nakamura M., Komoto S., Okada Y., Watanabe C., Kawaguchi A., Nagao S., Miura S., Interferon- α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels. Clinical and Experimental Immunology 2010 162 1 156 162 2-s2.0-77956512508 10.1111/j.1365-2249.2010.04222.x
63. Duffau P., Seneschal J., Nicco C., Richez C., Lazaro E., Douchet I., Bordes C., Viallard J., Goulvestre C., Pellegrin J., Weil B., Moreau J., Batteux F., Blanco P., Platelet CD154 potentiates interferon- α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Science Translational Medicine 2010 2 47 2-s2.0-77956454663 10.1126/scitranslmed.3001001 47ra63
64. Thacker S. G., Berthier C. C., Mattinzoli D., Rastaldi M. P., Kretzler M., Kaplan M. J., The detrimental effects of IFN- α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. Journal of Immunology 2010 185 7 4457 4469 2-s2.0-77958144092 10.4049/jimmunol.1001782
65. Koenig W., Karakas M., Zierer A., Herder C., Baumert J., Meisinger C., Thorand B., Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg study. Clinical Chemistry 2011 57 8 1196 1200 2-s2.0-79961069207 10.1373/clinchem.2011.165134
66. Tsimikas S., Brilakis E. S., Miller E. R., McConnell J. P., Lennon R. J., Kornman K. S., Witztum J. L., Berger P. B., Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. The New England Journal of Medicine 2005 353 1 46 57 2-s2.0-21444447949 10.1056/NEJMoa043175 (Pubitemid 41007806)
67. Svenungsson E., Jensen-Urstad K., Heimbürger M., Silveira A., Hamsten A., de Faire U., Witztum J. L., Frostegård J., Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001 104 16 1887 1893 2-s2.0-0035899949 (Pubitemid 32983229)
68. Frostegård J., Svenungsson E., Wu R., Gunnarsson I., Lundberg I. E., Klareskog L., Hörkkö S., Witztum J. L., Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis and Rheumatism 2005 52 1 192 200 2-s2.0-12344295255 10.1002/art.20780 (Pubitemid 40129248)
69. Lopez D., Garcia-Valladares I., Palafox-Sanchez C. A., de la Torre I. G., Kobayashi K., Matsuura E., Lopez L. R., Oxidized low-density lipoprotein/ β 2-glycoprotein I complexes and autoantibodies to oxLig-1/ β 2-glycoprotein I in patients with systemic lupns erythematosus and antiphospholipid syndrome. The American Journal of Clinical Pathology 2004 121 3 426 436 2-s2.0-1542317794 10.1309/2AUE-6HD4-W6TL-EUU5 (Pubitemid 38298177)
70. Hunt B. J., The endothelium in atherogenesis. Lupus 2000 9 3 189 193 2-s2.0-0034118121 (Pubitemid 30199261)
71. Hansson G. K., Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 2005 352 16 1685 1695 2-s2.0-17644412023 10.1056/NEJMra043430 (Pubitemid 40530235)
72. Tsouknos A., Nash G. B., Rainger G. E., Monocytes initiate a cycle of leukocyte recruitment when cocultured with endothelial cells. Atherosclerosis 2003 170 1 49 58 2-s2.0-0042261764 10.1016/S0021-9150(03)00288-0 (Pubitemid 37083563)
73. Moore K. J., Tabas I., Macrophages in the pathogenesis of atherosclerosis. Cell 2011 145 3 341 355 2-s2.0-79955535643 10.1016/j.cell.2011. 04.005
74. Huang Y., Wu Z., Riwanto M., Gao S., Levison B. S., Gu X., Fu X., Wagner M. A., Besler C., Gerstenecker G., Zhang R., Li X. M., DiDonato A. J., Gogonea V., Tang W. H., Smith J. D., Plow E. F., Fox P. L., Shih D. M., Lusis A. J., Fisher E. A., DiDonato J. A., Landmesser U., Hazen S. L., Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. Journal of Clinical Investigation 2013 123 9 3815 3828 10.1172/JCI67478
75. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D. J., Thong B. Y., Badsha H., Kalunian K., Charles C., Navab M., Fogelman A. M., Hahn B. H., Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis and Rheumatism 2006 54 8 2541 2549 2-s2.0-33746977703 10.1002/art.21976 (Pubitemid 44205015)
76. Wiesner G., Vaz M., Collier G., Seals D., Kaye D., Jennings G., Lambert G., Wilkinson D., Esler M., Leptin is released from the human brain: influence of adiposity and gender. Journal of Clinical Endocrinology and Metabolism 1999 84 7 2270 2274 2-s2.0-0033305752
77. Wallace A. M., McMahon A. D., Packard C. J., Kelly A., Shepherd J., Gaw A., Sattar N., Plasma leptin and the risk of cardiovascular disease in the West of Scotland coronary prevention study (WOSCOPS). Circulation 2001 104 25 3052 3056 2-s2.0-0035909997 (Pubitemid 34014056)
78. Payne G. A., Tune J. D., Knudson J. D., Leptin-induced endothelial dysfunction: a target for therapeutic interventions. Current Pharmaceutical Design 2014 20 4 603 608
79. McMahon M., Skaggs B. J., Grossman J. M., Sahakian L., Fitzgerald J., Wong W. K., Lourenco E. V., Ragavendra N., Charles-Schoeman C., Gorn A., Karpouzas G. A., Taylor M. B., Watson K. E., Weisman M. H., Wallace D. J., Hahn B. H., A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis and Rheumatology 2014 66 1 130 139 10.1002/art.38204
80. McMahon M., Skaggs B. J., Sahakian L., Grossman J., FitzGerald J., Ragavendra N., Charles-Schoeman C., Chernishof M., Gorn A., Witztum J. L., Wong W. K., Weisman M., Wallace D. J., la Cava A., Hahn B. H., High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Annals of the Rheumatic Diseases 2011 70 9 1619 1624 2-s2.0-80051471532 10.1136/ard.2010.142737
81. Amarilyo G., Iikuni N., Shi F. D., Liu A., Matarese G., la Cava A., Leptin promotes lupus T-cell autoimmunity. Clinical Immunology 2013 149 3 530 533 10.1016/j.clim.2013.09.002
82. Yu Y., Liu Y., Shi F. D., Zou H., Matarese G., la Cava A., Cutting edge: leptin-induced ROR γ t expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. Journal of Immunology 2013 190 7 3054 3058 10.4049/jimmunol.1203275
83. Madamanchi N. R., Vendrov A., Runge M. S., Oxidative stress and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 1 29 38 2-s2.0-11144225245 10.1161/01.ATV.0000150649.39934.13 (Pubitemid 40054251)
84. Mak A., Almsherq Z. A., Lai Y. W., Cheak A. A., Deng Y., Intracellular tubulo-reticular structures of peripheral blood mononuclear cells as an ultra-structural marker of disease activity in systemic lupus erythematosus: a pilot study. International Journal of Rheumatic Diseases 2013 16 6 692 697 10.1111/1756-185X.12195
85. Hassan S. Z., Gheita T. A., Kenawy S. A., Fahim A. T., El-Sorougy I. M., Abdou M. S., Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. International Journal of Rheumatic Diseases 2011 14 4 325 331 2-s2.0-80054699494 10.1111/j.1756-185X.2011.01630.x
86. Wang G., Pierangeli S. S., Papalardo E., Ansari G. A. S., Khan M. F., Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis and Rheumatism 2010 62 7 2064 2072 2-s2.0-77953503390 10.1002/art.27442
87. Huang W. N., Tso T. K., Huang H. Y., Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus. Rheumatology International 2007 27 5 453 458 2-s2.0-33847094136 10.1007/s00296-006-0233-1 (Pubitemid 46294980)
88. Vinay D. S., Kwon B. S., 4-1BB signaling beyond T cells. Cellular and Molecular Immunology 2011 8 4 281 284 2-s2.0-79954593616 10.1038/cmi.2010.82
89. Wang C., Lin G. H. Y., McPherson A. J., Watts T. H., Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews 2009 229 1 192 215 2-s2.0-65349153714 10.1111/j.1600-065X.2009.00765.x
90. Sun Y., Chen H. M., Subudhi S. K., Chen J., Koka R., Chen L., Fu Y. X., Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine 2002 8 12 1405 1413 2-s2.0-0036913169 10.1038/nm796 (Pubitemid 36019426)
91. Foell J., Strahotin S., O'Neil S. P., McCausland M. M., Suwyn C., Haber M., Chander P. N., Bapat A. S., Yan X., Chiorazzi N., Hoffmann M. K., Mittler R. S., CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB × NZW F1 mice. Journal of Clinical Investigation 2003 111 10 1505 1518 2-s2.0-0038312910 10.1172/JCI200317662 (Pubitemid 38063283)
92. Quek B. Z., Lim Y. C., Lin J. H. R., Tan T. E., Chan J., Biswas A., Schwarz H., CD137 enhances monocyte-ICAM-1 interactions in an E-selectin-dependent manner under flow conditions. Molecular Immunology 2010 47 9 1839 1847 2-s2.0-77952320875 10.1016/j.molimm.2009.11.010
93. Drenkard D., Becke F. M., Langstein J., Spruss T., Kunz-Schughart L. A., Teng E. T., Lim Y. C., Schwarz H., CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB Journal 2007 21 2 456 463 2-s2.0-33846784977 10.1096/fj.05-4739com (Pubitemid 46213493)
94. Olofsson P. S., Söderström L. Å., Wågsäter D., Sheikine Y., Ocaya P., Lang F., Rabu C., Chen L., Rudling M., Aukrust P., Hedin U., Paulsson-Berne G., Sirsjö A., Hansson G. K., CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008 117 10 1292 1301 2-s2.0-40549112657 10.1161/CIRCULATIONAHA.107.699173 (Pubitemid 351365671)
95. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., Richardson B., Demethylation of CD40LG on the inactive X in T cells from women with lupus. Journal of Immunology 2007 179 9 6352 6358 2-s2.0-38449116161
96. Zhou Y., Yuan J., Pan Y., Fei Y., Qiu X., Hu N., Luo Y., Lei W., Li Y., Long H., Sawalha A. H., Richardson B., Lu Q., T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clinical Immunology 2009 132 3 362 370 2-s2.0-67651152585 10.1016/j.clim.2009. 05.011
97. Yellin M. J., Thienel U., T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Current Rheumatology Reports 2000 2 1 24 31 2-s2.0-0034139373
98. Mach F., Schönbeck U., Sukhova G. K., Atkinson E., Libby P., Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998 394 6689 200 203 2-s2.0-2642608661 10.1038/28204 (Pubitemid 28325976)
99. Boumpas D. T., Furie R., Manzi S., Illei G. G., Wallace D. J., Balow J. E., Vaishnaw A., A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis and Rheumatism 2003 48 3 719 727 2-s2.0-0037333857 10.1002/art.10856 (Pubitemid 36302008)
100. Yang J., Chu Y., Yang X., Gao D., Zhu L., Yang X., Wan L., Li M., Th17 and natural treg cell population dynamics in systemic lupus erythematosus. Arthritis and Rheumatism 2009 60 5 1472 1483 2-s2.0-66049151440 10.1002/art.24499
101. van Es T., van Puijvelde G. H. M., Ramos O. H., Segers F. M. E., Joosten L. A., van den Berg W. B., Michon I. M., de Vos P., van Berkel T. J. C., Kuiper J., Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochemical and Biophysical Research Communications 2009 388 2 261 265 2-s2.0-69249213893 10.1016/j.bbrc.2009.07.152
102. Chen S., Crother T. R., Arditi M., Emerging role of IL-17 in atherosclerosis. Journal of Innate Immunity 2010 2 4 325 333 2-s2.0-77954062300 10.1159/000314626
103. Mak A., Tang C. S., Ho R. C., Serum tumour necrosis factor- α is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus 2013 22 3 254 261 10.1177/0961203312471872
104. Rho Y. H., Chung C. P., Oeser A., Solus J., Raggi P., Gebretsadik T., Shintani A., Stein C. M., Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. Journal of Rheumatology 2008 35 9 1789 1794 2-s2.0-54049117683
105. McHale J. F., Harari O. A., Marshall D., Haskard D. O., TNF- α and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. Journal of Immunology 1999 163 7 3993 4000 2-s2.0-0033214841 (Pubitemid 29450929)
106. Schiopu A., Bengtsson J., Söderberg I., Janciauskiene S., Lindgren S., Ares M. P. S., Shah P. K., Carlsson R., Nilsson J., Fredrikson G. N., Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004 110 14 2047 2052 2-s2.0-20844432027 10.1161/01.CIR.0000143162.56057.B5 (Pubitemid 39331920)
107. Palinski W., Miller E., Witztum J. L., Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proceedings of the National Academy of Sciences of the United States of America 1995 92 3 821 825 2-s2.0-0028895573 10.1073/pnas.92.3.821
108. Romero F. I., Amengual O., Atsumi T., Khamashta M. A., Tinahones F. J., Hughes G. R. V., Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti- β 2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. The British Journal of Rheumatology 1998 37 8 883 888 2-s2.0-0031856327
109. Hayem G., Nicaise-Roland P., Palazzo E., de Bandt M., Tubach F., Weber M., Meyer O., Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001 10 5 346 351 2-s2.0-0034993766 10.1191/096120301667475689 (Pubitemid 32520241)
110. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., Barshack I., Kopolovic J., Shoenfeld Y., Immunolocalization of β 2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999 99 17 2227 2230 2-s2.0-0032587108 (Pubitemid 29201126)
111. Valer P., Paul B., Eugenia B., Camelia B., Annexin A5 as independent predictive biomarker for subclinical atherosclerosis and endothelial dysfunction in systemic lupus erythematosus patients. Clinical Laboratory 2013 59 3-4 359 367
112. Ravanat C., Archipoff G., Beretz A., Freund A., Cazenve J. P., Freyssinet J. M., Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells. Biochemical Journal 1992 282 part 1 7 13 2-s2.0-0026505482
113. Hrycek A., Cieślik P., Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus. Rheumatology International 2012 32 5 1335 1342 10.1007/s00296-011-1793-2
114. Rand J. H., Wu X. X., Andree H. A. M., Ross J. B. A., Rusinova E., Gascon-Lema M. G., Calandri C., Harpel P. C., Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood 1998 92 5 1652 1660 2-s2.0-0032170963 (Pubitemid 28406869)
115. Clancy R. M., Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Current Rheumatology Reports 2000 2 1 39 43 10.1007/s11926-996-0067-6
116. Fraser D. A., Tenner A. J., Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. Journal of Immunology 2010 185 7 3932 3939 2-s2.0-77958140658 10.4049/jimmunol.1002080
117. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D. S., Weinrauch Y., Zychlinsky A., Neutrophil extracellular traps kill bacteria. Science 2004 303 5663 1532 1535 2-s2.0-1542287347 10.1126/science.1092385 (Pubitemid 38314426)
118. Garcia-Romo G. S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., Punaro M., Baisch J., Guiducci C., Coffman R. L., Barrat F. J., Banchereau J., Pascual V., Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Science Translational Medicine 2011 3 73 2-s2.0-79952476762 10.1126/scitranslmed.3001201 73ra20
119. Gupta A. K., Joshi M. B., Philippova M., Erne P., Hasler P., Hahn S., Resink T. J., Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Letters 2010 584 14 3193 3197 2-s2.0-77954176096 10.1016/j.febslet.2010.06.006
120. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V., Bassett R., Amuro H., Fukuhara S., Ito T., Liu Y., Gilliet M., Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Science Translational Medicine 2011 3 73 2-s2.0-79952468782 10.1126/scitranslmed.3001180 73ra19
121. Yamaoka J., Kabashima K., Kawanishi M., Toda K., Miyachi Y., Cytotoxicity of IFN- γ and TNF- α for vascular endothelial cell is mediated by nitric oxide. Biochemical and Biophysical Research Communications 2002 291 4 780 786 2-s2.0-0036291333 10.1006/bbrc.2002.6487 (Pubitemid 34694343)
122. Denny M. F., Thacker S., Mehta H., Somers E. C., Dodick T., Barrat F. J., McCune W. J., Kaplan M. J., Interferon- α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007 110 8 2907 2915 2-s2.0-35548948085 10.1182/blood-2007-05-089086 (Pubitemid 350006944)
123. Kahlenberg J. M., Thacker S. G., Berthier C. C., Cohen C. D., Kretzler M., Kaplan M. J., Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. Journal of Immunology 2011 187 11 6143 6156 2-s2.0-82755162135 10.4049/jimmunol.1101284
124. Rodríguez-Carrio J., Alperi-López M., López P., Alonso-Castro S., Ballina-García F. J., Suárez A., Angiogenic T cells are decreased in rheumatoid arthritis patients. Annals of the Rheumatic Diseases 2014 10.1136/annrheumdis-2013-204250
125. Thacker S. G., Duquaine D., Park J., Kaplan M. J., Lupus-prone New Zealand Black/New Zealand white F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 2010 19 3 288 299 2-s2.0-77749251784 10.1177/0961203309353773
126. Denny M. F., Yalavarthi S., Zhao W., Thacker S. G., Anderson M., Sandy A. R., McCune W. J., Kaplan M. J., A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. Journal of Immunology 2010 184 6 3284 3297 10.4049/jimmunol.0902199
127. Somers E. C., Zhao W., Lewis E. E., Wang L., Wing J. J., Sundaram B., Kazerooni E. A., McCune W. J., Kaplan M. J., Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE 2012 7 5 e37000